HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily

According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date,...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2013-12, Vol.6 (6), p.1591-1594
Main Authors: IENI, A, BARRESI, V, GIUFFRÈ, G, CARUSO, R.A, LANZAFAME, S, VILLARI, L, SALOMONE, E, ROZ, E, CABIBI, D, FRANCO, V, CERTO, G, LABATE, A, NAGAR, C, MAGLIOLO, E, BROGGI, B, FAZZARI, C, ITALIA, F, TUCCARI, G
Format: Article
Language:English
Subjects:
Antigens
Cancer therapies
Chemotherapy
Cloning
Cytoplasm
gastric adenocarcinoma
Gastric cancer
Gene amplification
HER2 status
Immunotherapy
Laboratories
Monoclonal antibodies
Mortality
Multivariate analysis
Oncology
Proteins
Sicily
Statistical analysis
Studies
Targeted cancer therapy
trastuzumab
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3
cites cdi_FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3
container_end_page 1594
container_issue 6
container_start_page 1591
container_title Oncology letters
container_volume 6
creator IENI, A
BARRESI, V
GIUFFRÈ, G
CARUSO, R.A
LANZAFAME, S
VILLARI, L
SALOMONE, E
ROZ, E
CABIBI, D
FRANCO, V
CERTO, G
LABATE, A
NAGAR, C
MAGLIOLO, E
BROGGI, B
FAZZARI, C
ITALIA, F
TUCCARI, G
description According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of histotype, grade, stage and Ki-67 expression were also analyzed. HER2 overexpression was encountered in 17.43% of all the gastric adenocarcinomas, which was consistent with the results that have been reported elsewhere in the literature. A progressive increase in HER2 overexpression was observed, from the poorly cohesive histotype to the tubular adenocarcinomas and gastric hepatoid adenocarcinomas. HER2 overexpression was significantly associated with a high grade, advanced stage and high Ki-67 labeling index. Further investigations performed jointly by pathologists and oncologists within the geographical area of the present study should confirm that the association of trastuzumab with chemotherapy results in an improvement of survival in patients with AGC.
doi_str_mv 10.3892/ol.2013.1611
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3833944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826581852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYMotqx981kCgvjgrLnJTDbxoVBKtUJB8ONNCHcymZqSmazJzML-92a6df0IgdyQH4dzcgh5DmwtlOZvY1hzBmINEuAROYWN5hUwxR8f5019Qs5yvmNlNRKUkk_JCa-5LFc4Jd-vrz5zmiec5kz9SLHb4WhdR28xT8lbajFZP8YB39ELmtyUYt46O_mdo8McJm_deM_hiGGffaZ9igP94q0P-2fkSY8hu7OHc0W-vb_6enld3Xz68PHy4qaydS2mCgRvHasRGTLd21Zq65RthJKiUY3olNN1hxr6tuYO2xYFww30G92oFqTuxIqcH3S3czu47t4SBrNNfsC0NxG9-fdl9D_MbdwZoYTQxcOKvH4QSPHn7PJkBp-tCwFHF-dsQHHZKFANL-jL_9C7OKcSvlBacFlLJRbBNwfKlv_KyfVHM8DM0pyJwSzNmaW5gr_4O8AR_t1TAV4dgLzFsfNdzH_ShYrJZUOjQfwCsfahTQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932646834</pqid></control><display><type>article</type><title>HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily</title><source>Open Access: PubMed Central</source><creator>IENI, A ; BARRESI, V ; GIUFFRÈ, G ; CARUSO, R.A ; LANZAFAME, S ; VILLARI, L ; SALOMONE, E ; ROZ, E ; CABIBI, D ; FRANCO, V ; CERTO, G ; LABATE, A ; NAGAR, C ; MAGLIOLO, E ; BROGGI, B ; FAZZARI, C ; ITALIA, F ; TUCCARI, G</creator><creatorcontrib>IENI, A ; BARRESI, V ; GIUFFRÈ, G ; CARUSO, R.A ; LANZAFAME, S ; VILLARI, L ; SALOMONE, E ; ROZ, E ; CABIBI, D ; FRANCO, V ; CERTO, G ; LABATE, A ; NAGAR, C ; MAGLIOLO, E ; BROGGI, B ; FAZZARI, C ; ITALIA, F ; TUCCARI, G</creatorcontrib><description>According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of histotype, grade, stage and Ki-67 expression were also analyzed. HER2 overexpression was encountered in 17.43% of all the gastric adenocarcinomas, which was consistent with the results that have been reported elsewhere in the literature. A progressive increase in HER2 overexpression was observed, from the poorly cohesive histotype to the tubular adenocarcinomas and gastric hepatoid adenocarcinomas. HER2 overexpression was significantly associated with a high grade, advanced stage and high Ki-67 labeling index. Further investigations performed jointly by pathologists and oncologists within the geographical area of the present study should confirm that the association of trastuzumab with chemotherapy results in an improvement of survival in patients with AGC.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2013.1611</identifier><identifier>PMID: 24260051</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Antigens ; Cancer therapies ; Chemotherapy ; Cloning ; Cytoplasm ; gastric adenocarcinoma ; Gastric cancer ; Gene amplification ; HER2 status ; Immunotherapy ; Laboratories ; Monoclonal antibodies ; Mortality ; Multivariate analysis ; Oncology ; Proteins ; Sicily ; Statistical analysis ; Studies ; Targeted cancer therapy ; trastuzumab ; Tumors</subject><ispartof>Oncology letters, 2013-12, Vol.6 (6), p.1591-1594</ispartof><rights>Copyright © 2013, Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2013</rights><rights>Copyright © 2013, Spandidos Publications 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3</citedby><cites>FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833944/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833944/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24260051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IENI, A</creatorcontrib><creatorcontrib>BARRESI, V</creatorcontrib><creatorcontrib>GIUFFRÈ, G</creatorcontrib><creatorcontrib>CARUSO, R.A</creatorcontrib><creatorcontrib>LANZAFAME, S</creatorcontrib><creatorcontrib>VILLARI, L</creatorcontrib><creatorcontrib>SALOMONE, E</creatorcontrib><creatorcontrib>ROZ, E</creatorcontrib><creatorcontrib>CABIBI, D</creatorcontrib><creatorcontrib>FRANCO, V</creatorcontrib><creatorcontrib>CERTO, G</creatorcontrib><creatorcontrib>LABATE, A</creatorcontrib><creatorcontrib>NAGAR, C</creatorcontrib><creatorcontrib>MAGLIOLO, E</creatorcontrib><creatorcontrib>BROGGI, B</creatorcontrib><creatorcontrib>FAZZARI, C</creatorcontrib><creatorcontrib>ITALIA, F</creatorcontrib><creatorcontrib>TUCCARI, G</creatorcontrib><title>HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of histotype, grade, stage and Ki-67 expression were also analyzed. HER2 overexpression was encountered in 17.43% of all the gastric adenocarcinomas, which was consistent with the results that have been reported elsewhere in the literature. A progressive increase in HER2 overexpression was observed, from the poorly cohesive histotype to the tubular adenocarcinomas and gastric hepatoid adenocarcinomas. HER2 overexpression was significantly associated with a high grade, advanced stage and high Ki-67 labeling index. Further investigations performed jointly by pathologists and oncologists within the geographical area of the present study should confirm that the association of trastuzumab with chemotherapy results in an improvement of survival in patients with AGC.</description><subject>Antigens</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Cloning</subject><subject>Cytoplasm</subject><subject>gastric adenocarcinoma</subject><subject>Gastric cancer</subject><subject>Gene amplification</subject><subject>HER2 status</subject><subject>Immunotherapy</subject><subject>Laboratories</subject><subject>Monoclonal antibodies</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Proteins</subject><subject>Sicily</subject><subject>Statistical analysis</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><subject>trastuzumab</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpdkd1rFDEUxYMotqx981kCgvjgrLnJTDbxoVBKtUJB8ONNCHcymZqSmazJzML-92a6df0IgdyQH4dzcgh5DmwtlOZvY1hzBmINEuAROYWN5hUwxR8f5019Qs5yvmNlNRKUkk_JCa-5LFc4Jd-vrz5zmiec5kz9SLHb4WhdR28xT8lbajFZP8YB39ELmtyUYt46O_mdo8McJm_deM_hiGGffaZ9igP94q0P-2fkSY8hu7OHc0W-vb_6enld3Xz68PHy4qaydS2mCgRvHasRGTLd21Zq65RthJKiUY3olNN1hxr6tuYO2xYFww30G92oFqTuxIqcH3S3czu47t4SBrNNfsC0NxG9-fdl9D_MbdwZoYTQxcOKvH4QSPHn7PJkBp-tCwFHF-dsQHHZKFANL-jL_9C7OKcSvlBacFlLJRbBNwfKlv_KyfVHM8DM0pyJwSzNmaW5gr_4O8AR_t1TAV4dgLzFsfNdzH_ShYrJZUOjQfwCsfahTQ</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>IENI, A</creator><creator>BARRESI, V</creator><creator>GIUFFRÈ, G</creator><creator>CARUSO, R.A</creator><creator>LANZAFAME, S</creator><creator>VILLARI, L</creator><creator>SALOMONE, E</creator><creator>ROZ, E</creator><creator>CABIBI, D</creator><creator>FRANCO, V</creator><creator>CERTO, G</creator><creator>LABATE, A</creator><creator>NAGAR, C</creator><creator>MAGLIOLO, E</creator><creator>BROGGI, B</creator><creator>FAZZARI, C</creator><creator>ITALIA, F</creator><creator>TUCCARI, G</creator><general>D.A. Spandidos</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131201</creationdate><title>HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily</title><author>IENI, A ; BARRESI, V ; GIUFFRÈ, G ; CARUSO, R.A ; LANZAFAME, S ; VILLARI, L ; SALOMONE, E ; ROZ, E ; CABIBI, D ; FRANCO, V ; CERTO, G ; LABATE, A ; NAGAR, C ; MAGLIOLO, E ; BROGGI, B ; FAZZARI, C ; ITALIA, F ; TUCCARI, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antigens</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Cloning</topic><topic>Cytoplasm</topic><topic>gastric adenocarcinoma</topic><topic>Gastric cancer</topic><topic>Gene amplification</topic><topic>HER2 status</topic><topic>Immunotherapy</topic><topic>Laboratories</topic><topic>Monoclonal antibodies</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Proteins</topic><topic>Sicily</topic><topic>Statistical analysis</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><topic>trastuzumab</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IENI, A</creatorcontrib><creatorcontrib>BARRESI, V</creatorcontrib><creatorcontrib>GIUFFRÈ, G</creatorcontrib><creatorcontrib>CARUSO, R.A</creatorcontrib><creatorcontrib>LANZAFAME, S</creatorcontrib><creatorcontrib>VILLARI, L</creatorcontrib><creatorcontrib>SALOMONE, E</creatorcontrib><creatorcontrib>ROZ, E</creatorcontrib><creatorcontrib>CABIBI, D</creatorcontrib><creatorcontrib>FRANCO, V</creatorcontrib><creatorcontrib>CERTO, G</creatorcontrib><creatorcontrib>LABATE, A</creatorcontrib><creatorcontrib>NAGAR, C</creatorcontrib><creatorcontrib>MAGLIOLO, E</creatorcontrib><creatorcontrib>BROGGI, B</creatorcontrib><creatorcontrib>FAZZARI, C</creatorcontrib><creatorcontrib>ITALIA, F</creatorcontrib><creatorcontrib>TUCCARI, G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IENI, A</au><au>BARRESI, V</au><au>GIUFFRÈ, G</au><au>CARUSO, R.A</au><au>LANZAFAME, S</au><au>VILLARI, L</au><au>SALOMONE, E</au><au>ROZ, E</au><au>CABIBI, D</au><au>FRANCO, V</au><au>CERTO, G</au><au>LABATE, A</au><au>NAGAR, C</au><au>MAGLIOLO, E</au><au>BROGGI, B</au><au>FAZZARI, C</au><au>ITALIA, F</au><au>TUCCARI, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>6</volume><issue>6</issue><spage>1591</spage><epage>1594</epage><pages>1591-1594</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>According to the ToGA trial, HER2 has been shown to be predictive for the success of treatment with trastuzumab in advanced gastric cancer (AGC). A number of studies have analyzed HER-2/neu overexpression in gastric carcinoma and identified the rate of HER2 positivity to be markedly varied. To date, the prevalence of HER2 overexpression in Sicilian people with AGC is unknown. Therefore, in the present study, a retrospective immunohistochemical analysis of HER2 was performed in a cohort of 304 AGC samples that were obtained from the archives of 10 Sicilian anatomopathological diagnostic units in order to verify the positive rate of HER2-positive cases. Furthermore, the characteristics of histotype, grade, stage and Ki-67 expression were also analyzed. HER2 overexpression was encountered in 17.43% of all the gastric adenocarcinomas, which was consistent with the results that have been reported elsewhere in the literature. A progressive increase in HER2 overexpression was observed, from the poorly cohesive histotype to the tubular adenocarcinomas and gastric hepatoid adenocarcinomas. HER2 overexpression was significantly associated with a high grade, advanced stage and high Ki-67 labeling index. Further investigations performed jointly by pathologists and oncologists within the geographical area of the present study should confirm that the association of trastuzumab with chemotherapy results in an improvement of survival in patients with AGC.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>24260051</pmid><doi>10.3892/ol.2013.1611</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2013-12, Vol.6 (6), p.1591-1594
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3833944
source Open Access: PubMed Central
subjects Antigens
Cancer therapies
Chemotherapy
Cloning
Cytoplasm
gastric adenocarcinoma
Gastric cancer
Gene amplification
HER2 status
Immunotherapy
Laboratories
Monoclonal antibodies
Mortality
Multivariate analysis
Oncology
Proteins
Sicily
Statistical analysis
Studies
Targeted cancer therapy
trastuzumab
Tumors
title HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A31%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2%20status%20in%20advanced%20gastric%20carcinoma:%20A%20retrospective%20multicentric%20analysis%20from%20Sicily&rft.jtitle=Oncology%20letters&rft.au=IENI,%20A&rft.date=2013-12-01&rft.volume=6&rft.issue=6&rft.spage=1591&rft.epage=1594&rft.pages=1591-1594&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2013.1611&rft_dat=%3Cproquest_pubme%3E1826581852%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-132be04aa0a09fcb69ce8c538635853d8e94da91fb42eabba30a71f7958b169d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1932646834&rft_id=info:pmid/24260051&rfr_iscdi=true